Policy & Regulation
Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SARS-CoV-2, Including Alpha, Beta, and Gamma Strains, in Preclinical Studies
24 September 2021 - - US-based synthetic biology and genomics company Twist Bioscience Corp's (NASDAQ: TWST) internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent bind...
SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
24 September 2021 - - An independent Data Safety Monitoring Board has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-...
Reven Completes the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients
24 September 2021 - - US-based biotechnology and pharmaceutical company Reven Holdings, Inc has completed Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Reven's lead anti-sep...
Pfizer's Dolsten Named to Agilent Board of Directors
24 September 2021 - - Dr. Mikael Dolsten, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer Inc. has been elected to US-based Agilent Technologies, Inc's...
Long-Term Crysvita Treatment Reduces the Burden of Disease in Adults With X-Linked Hypophosphataemia, a Rare Genetic Metabolic Bone Disease
24 September 2021 - - New data has been published highlighting the sustained benefits of treatment with Crysvita (burosumab) in adults with X-linked hypophosphataemia, a rare genetic metabolic bone di...
Pulmotect Touts Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 against COVID-19
24 September 2021 - - US-based biotechnology company Pulmotect, Inc has posted positive topline results from the first of two Phase-2 clinical trials undertaken with the support of the US Department o...
Related Headlines

Bavarian Nordic gets final approval of COVID-19 booster vaccine funding agreement

Phenomenex launches NEW Biozen SEC Size Exclusion Chromatography Columns

Inhibikase Therapeutics receives research grant to assess IkT-148009 in preclinical model for Multiple System Atrophy

Innovent Biologics doses first plaque psoriasis patient in 23p19 subunit antibody injection phase two clinical trial

The Center for Breakthrough Medicines names new CEO

DiNAQOR names new executive vice president, Medical Devices

Taysha Receives Orphan Drug Designation from the European Commission for TSHA-102 for the Treatment of Rett Syndrome

OncoNano Medicine Expands Research Collaboration with UT Southwestern Medical Center to Advance Development of New Cancer Therapies

Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical officer

Cyclica, Impact Therapeutics Team Up to Advance Differentiated Anti-Cancer Drug Development

Veklury Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19

CytoDyn Receives Clearance from Brazil's FDA to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)

Arcturus Therapeutics Receives Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

Zymo wins CE IVD Mark for EZ DNA Methylation-Lightning Kit with bisulfite technology for clinical applications

AbCellera signs multi-year collaboration and license agreement with Everest Medicines